Biogen Inc Stock Current Valuation
| IDP Stock | EUR 211.50 6.50 3.17% |
Valuation analysis of Biogen Inc helps investors to measure Biogen's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Biogen's price fluctuation is very steady at this time. Calculation of the real value of Biogen Inc is based on 3 months time horizon. Increasing Biogen's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Biogen Inc is useful when determining the fair value of the Biogen stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Biogen. Since Biogen is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biogen Stock. However, Biogen's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 211.5 | Real 164.97 | Hype 211.5 | Naive 207.05 |
The real value of Biogen Stock, also known as its intrinsic value, is the underlying worth of Biogen Inc Company, which is reflected in its stock price. It is based on Biogen's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Biogen's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Biogen's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Biogen Inc helps investors to forecast how Biogen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biogen more accurately as focusing exclusively on Biogen's fundamentals will not take into account other important factors: Biogen Inc Company Current Valuation Analysis
Biogen's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Biogen Current Valuation | 41.13 B |
Most of Biogen's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biogen Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Biogen Inc has a Current Valuation of 41.13 B. This is 186.32% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The current valuation for all Germany stocks is 147.38% lower than that of the firm.
Biogen Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biogen's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biogen could also be used in its relative valuation, which is a method of valuing Biogen by comparing valuation metrics of similar companies.Biogen is rated third overall in current valuation category among its peers.
Biogen Fundamentals
| Return On Equity | 0.24 | |||
| Return On Asset | 0.0778 | |||
| Profit Margin | 0.30 % | |||
| Operating Margin | 0.30 % | |||
| Current Valuation | 41.13 B | |||
| Shares Outstanding | 144.49 M | |||
| Shares Owned By Insiders | 0.68 % | |||
| Shares Owned By Institutions | 89.93 % | |||
| Price To Earning | 14.27 X | |||
| Price To Book | 3.24 X | |||
| Price To Sales | 3.84 X | |||
| Revenue | 10.17 B | |||
| Gross Profit | 7.9 B | |||
| EBITDA | 4.36 B | |||
| Net Income | 3.05 B | |||
| Cash And Equivalents | 2.54 B | |||
| Cash Per Share | 16.85 X | |||
| Total Debt | 6.28 B | |||
| Debt To Equity | 0.72 % | |||
| Current Ratio | 2.12 X | |||
| Book Value Per Share | 92.98 X | |||
| Cash Flow From Operations | 1.38 B | |||
| Earnings Per Share | 19.22 X | |||
| Price To Earnings To Growth | 36.01 X | |||
| Target Price | 413.19 | |||
| Number Of Employees | 8.72 K | |||
| Beta | 0.22 | |||
| Market Capitalization | 36.91 B | |||
| Total Asset | 24.55 B | |||
| Z Score | 3.0 | |||
| Net Asset | 24.55 B |
About Biogen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biogen Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biogen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biogen Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Biogen Stock
When determining whether Biogen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biogen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biogen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biogen Inc Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.